Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NanoFense is a proprietary antimicrobial coating technology developed by NanoSafe Inc. that utilizes silver nanoparticles to provide persistent protection against a broad spectrum of pathogens, including bacteria, viruses, and fungi. The technology is primarily designed for integration into textiles and surfaces, such as face masks and personal protective equipment (PPE), to enhance their self-disinfecting capabilities. The mechanism of action involves the controlled, sustained release of silver ions ($Ag^+$), which exert antimicrobial effects by disrupting microbial cell membranes, denaturing essential metabolic enzymes through binding with thiol groups, and interfering with genomic replication by interacting with microbial DNA. NanoFense was notably deployed during the COVID-19 pandemic to reduce the risk of pathogen transmission via medical fabrics and surfaces. As a material-integrated solution, it is typically categorized as a medical device component or a biocidal treatment rather than a systemic pharmaceutical agent.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on NanoFense.